Published in Addiction on October 01, 2003
The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int (2015) 1.98
Insomnia. JAMA (2013) 1.88
Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav (2008) 1.36
Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician (2007) 1.20
The medicalization of sleeplessness: a public health concern. Am J Public Health (2011) 1.19
Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br J Clin Pharmacol (2007) 1.17
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med (2007) 1.17
Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br J Gen Pract (2008) 1.16
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep (2007) 1.07
Treatment options for sleep disturbances during alcohol recovery. J Addict Dis (2007) 1.05
Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol (2008) 1.01
The clinical and forensic toxicology of Z-drugs. J Med Toxicol (2013) 1.00
Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol (2008) 0.97
Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry (2010) 0.96
Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens. Neuropsychopharmacology (2014) 0.89
Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol (2012) 0.89
Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Pharmacol (2009) 0.88
Zolpidem Use Associated With Increased Risk of Pyogenic Liver Abscess: A Case-Control Study in Taiwan. Medicine (Baltimore) (2015) 0.87
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther (2009) 0.87
Modest abuse-related subjective effects of zolpidem in drug-naive volunteers. Behav Pharmacol (2011) 0.87
Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment. PLoS One (2014) 0.84
Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addict Sci Clin Pract (2016) 0.83
Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol (2013) 0.82
A case of Zolpidem dependence successfully detoxified with gabapentin. Indian J Psychiatry (2013) 0.81
Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol (2013) 0.80
Forensic imaging for causal investigation of death. Korean J Radiol (2014) 0.79
Circadian dysregulation, zolpidem dependence, and withdrawal seizure in a resident physician performing shift work. Am J Addict (2012) 0.79
Prescription Sedative Misuse and Abuse. Yale J Biol Med (2015) 0.78
Flavonoid Myricetin Modulates GABA(A) Receptor Activity through Activation of Ca(2+) Channels and CaMK-II Pathway. Evid Based Complement Alternat Med (2012) 0.78
The effects of repeated zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: comparison with diazepam. Psychopharmacology (Berl) (2014) 0.78
Quetiapine treatment of zolpidem dependence. Am J Addict (2007) 0.78
Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) (2016) 0.77
Prior authorization of newer insomnia medications in managed care: is it cost saving? J Clin Sleep Med (2007) 0.77
Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol (2011) 0.77
Treatment of Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea During and After Menopause: Therapeutic Approaches. Curr Psychiatry Rev (2015) 0.77
Prevalence and Predictors of Prescription Sleep Aid Use among Individuals with DSM-5 Insomnia: The Role of Hyperarousal. Sleep (2016) 0.77
Azole interactions with multidrug therapy in pediatric oncology. Eur J Clin Pharmacol (2012) 0.76
Non-medical use of olanzapine by people on methadone treatment. BJPsych Bull (2016) 0.75
Evaluation of trazodone and quetiapine for insomnia: an observational study in psychiatric inpatients. Prim Care Companion CNS Disord (2013) 0.75
Neuroscience: Lack of inhibition leads to abuse. Nature (2010) 0.75
Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence. J Addict (2016) 0.75
Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: a case report. J Med Case Rep (2010) 0.75
Addictive evidence. Can Fam Physician (2008) 0.75
The effects of music relaxation and muscle relaxation techniques on sleep quality and emotional measures among individuals with posttraumatic stress disorder. Ment Illn (2012) 0.75
High-dose zolpidem withdrawal seizure in a patient with spinocerebellar ataxia. Prim Care Companion CNS Disord (2011) 0.75
Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review. CNS Drugs (2016) 0.75
Medical treatment of dystonia. J Clin Mov Disord (2016) 0.75
Raising awareness about sleep disorders. Lung India (2017) 0.75
Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats. Psychopharmacology (Berl) (2017) 0.75
High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review. Ind Psychiatry J (2017) 0.75
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry (1994) 48.75
The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry (1988) 12.83
Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav (1999) 3.20
Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity. Acta Psychiatr Scand (2000) 2.98
Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry (1999) 2.97
Prevalence of suicide ideation and suicide attempts in nine countries. Psychol Med (1999) 2.50
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry (1996) 2.48
Sex differences in rates of depression: cross-national perspectives. J Affect Disord (1994) 2.25
Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl (1996) 2.14
Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults. Psychol Med (2003) 2.07
[Fever of uncertain origin]. Internist (Berl) (1994) 2.02
Procedural validity of standardized symptom questions for the assessment of psychotic symptoms--a comparison of the DIS with two clinical methods. Compr Psychiatry (1988) 1.99
An international study of psychological problems in primary care. Preliminary report from the World Health Organization Collaborative Project on 'Psychological Problems in General Health Care'. Arch Gen Psychiatry (1993) 1.86
Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (2001) 1.86
Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry (2001) 1.85
Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. J Natl Cancer Inst (1987) 1.73
The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am (2001) 1.72
Parental alcohol use disorders and alcohol use and disorders in offspring: a community study. Psychol Med (2002) 1.71
Gender differences in adolescents and young adults with suicidal behaviour. Acta Psychiatr Scand (2001) 1.71
Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica. J Nat Prod (1996) 1.70
Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry (2000) 1.68
Parental psychopathology, parenting styles, and the risk of social phobia in offspring: a prospective-longitudinal community study. Arch Gen Psychiatry (2000) 1.63
The cross-national epidemiology of panic disorder. Arch Gen Psychiatry (1997) 1.61
Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging (2008) 1.59
Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults? Eur Psychiatry (2000) 1.58
The Early Developmental Stages of Psychopathology Study (EDSP): a methodological update. Eur Addict Res (2000) 1.56
[Use of drugs in residents of homes for the elderly and nursing homes in comparison with patients in ambulatory care or without need of care]. Dtsch Med Wochenschr (2002) 1.54
The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend (2001) 1.52
Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry (1998) 1.51
Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. Int J Clin Pharmacol Biopharm (1978) 1.50
Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psychol Med (1999) 1.50
The CIDI-core substance abuse and dependence questions: cross-cultural and nosological issues. The WHO/ADAMHA Field Trial. Br J Psychiatry (1991) 1.48
The location of drug binding sites in human serum albumin. Biochem Pharmacol (1981) 1.48
One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety (2001) 1.46
Risk factors for new depressive episodes in primary health care: an international prospective 12-month follow-up study. Psychol Med (2002) 1.44
Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults. Psychol Med (2003) 1.44
Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J (1997) 1.43
Management of patients with peripheral arterial disease in primary care: a cross-sectional study in Germany. Int J Clin Pract (2010) 1.42
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet (1988) 1.42
Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. Biochem Pharmacol (1977) 1.40
Coronary anomaly in Behçet's syndrome. Rheumatol Int (1997) 1.40
[Innovation instead of imitation -- news in drug therapy]. Dtsch Med Wochenschr (2005) 1.39
Inhibition of herpesvirus DNA synthesis by 9-beta-D-arabinofuranosyladenine in cellular and cell-free systems. Ann N Y Acad Sci (1977) 1.39
[Fractures of vital teeth under chronic pain therapy with oxycodone]. Dtsch Med Wochenschr (2006) 1.38
Action of bleomycin on DNA and RNA. Eur J Biochem (1972) 1.38
Panic and panic disorder in the United States. Am J Psychiatry (1994) 1.37
Characterization of the autoantigen La as a nucleic acid-dependent ATPase/dATPase with melting properties. Cell (1990) 1.36
Bacteria of the Genus Roseobacter Associated with the Toxic Dinoflagellate Prorocentrum lima. Protist (2009) 1.35
Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest (1998) 1.30
Rates of psychiatric disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. Int J Obes Relat Metab Disord (2000) 1.29
Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. Curr Med Res Opin (2005) 1.29
Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl (1998) 1.29
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Association of La and Ro antigens with intracellular structures in HEp-2 carcinoma cells. Proc Natl Acad Sci U S A (1986) 1.26
Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci (1998) 1.25
The La antigen shuttles between the nucleus and the cytoplasm in CV-1 cells. Mol Cell Biochem (1989) 1.23
Interferon production in patients infected with HIV-1. J Infect Dis (1989) 1.23
Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. Mol Pharmacol (1982) 1.22
High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) (2008) 1.22
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Origin of insulin receptor-like tyrosine kinases in marine sponges. Biol Bull (1999) 1.18
Detection of human immunodeficiency virus-1 nucleic acid on inactivated filter paper disks by polymerase chain reaction and microtiter plate assay. Microbiol Immunol (1994) 1.17
Transport of mRNA from nucleus to cytoplasm. Prog Nucleic Acid Res Mol Biol (1987) 1.17
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens (2009) 1.16
Inhibitors acting on nucleic acid synthesis in an oncogenic RNA virus. Nat New Biol (1971) 1.15
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis (1994) 1.14
Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS. J Immunol (1990) 1.14
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol (2008) 1.14
Clinical pharmacokinetics of articaine. Clin Pharmacokinet (1997) 1.13
Diagnosing major depression in the elderly: evidence for response bias in standardized diagnostic interviews? J Psychiatr Res (1994) 1.13
Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother (1990) 1.12
Intracellular distribution of the La antigen in CV-1 cells after herpes simplex virus type 1 infection compared with the localization of U small nuclear ribonucleoprotein particles. J Gen Virol (1989) 1.11
The comparison of beta-thymosin homologues among metazoa supports an arthropod-nematode clade. J Mol Evol (2000) 1.11
Localization of Epstein-Barr virus-encoded RNAs EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1992) 1.11
Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry (2003) 1.11
Expression of silicatein and collagen genes in the marine sponge Suberites domuncula is controlled by silicate and myotrophin. Eur J Biochem (2000) 1.11
DSM-IV panic attacks and panic disorder in a community sample of adolescents and young adults: how specific are panic attacks? J Psychiatr Res (1999) 1.10
A comparison of two diagnostic methods. Clinical ICD diagnoses vs DSM-III and Research Diagnostic Criteria using the Diagnostic Interview Schedule (version 2). Arch Gen Psychiatry (1985) 1.10
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther (2000) 1.10
Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord (2004) 1.09
Covariates of cannabis use progression in a representative population sample of adolescents: a prospective examination of vulnerability and risk factors. Addiction (1999) 1.09
Mature mRNA is selectively released from the nuclear matrix by an ATP/dATP-dependent mechanism sensitive to topoisomerase inhibitors. J Biol Chem (1987) 1.08
Primmorphs generated from dissociated cells of the sponge Suberites domuncula: a model system for studies of cell proliferation and cell death. Mech Ageing Dev (1998) 1.07
Comorbidity patterns in adolescents and young adults with suicide attempts. Eur Arch Psychiatry Clin Neurosci (1998) 1.07
Phosphorylation of arabinofuranosylthymine in non-infected and herpesvirus (TK+ and TK-)-infected cells. J Gen Virol (1979) 1.06
Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest (2006) 1.06
The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol (2005) 1.05
Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol Pharmacol (2009) 1.05
Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis (2006) 1.05
DSM-IV alcohol disorders in a general population sample of adolescents and young adults. Addiction (1998) 1.05
Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J Psychopharmacol (2008) 1.04
Inhibition of GABA and benzodiazepine receptor binding by penicillins. Neurosci Lett (1980) 1.04
Mode of action of 9-beta-D-arabinofuranosyladenine on the synthesis of DNA, RNA, and protein in vivo and in vitro. Cancer Res (1975) 1.04
ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. J Neural Transm (Vienna) (2001) 1.03
Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Br J Psychiatry Suppl (1996) 1.03
[Prevalence, detection and prescribing behavior in depressive syndromes. A German federal family physician study]. Nervenarzt (2002) 1.03